Quotes 5-day view Real-time Euronext Paris
06/07/2021
06/08/2021
06/09/2021
06/10/2021
06/11/2021
Date
2.9(c)
2.92(c)
2.915(c)
2.91(c)
2.89(c)
Last
68 571
47 134
79 109
29 113
32 083
Volume
-2.19% +0.69% -0.17% -0.17% -0.69% Change
Sales 2021
11,1 M 13,4 M 13,4 M
Net income 2021
-27,1 M -32,8 M -32,8 M
Net cash position 2021
12,6 M 15,2 M 15,2 M
P/E ratio 2021
-9,03x
Yield 2021
-
Sales 2022
8,10 M 9,80 M 9,80 M
Net income 2022
-32,7 M -39,6 M -39,6 M
Net Debt 2022
19,6 M 23,7 M 23,7 M
P/E ratio 2022
-7,41x
Yield 2022
-
Capitalization
242 M 292 M 293 M
EV / Sales 2021
20,6x
EV / Sales 2022
32,3x
Nbr of Employees
139
Free-Float
34,7%
Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.
The company's four lead clinical-stage programs are: TG4001 for HPV positive...
05/27 BioInvent, Transgene Win US FDA Nod For Phase 1/2a Study of Cancer Vaccine MT
05/27 BIOINVENT INTERNATIONAL : and Transgene receive IND approval from the U.S. FDA ..AQ
04/28 Global markets live : Microsoft, Apple, Tesla...04/27 TRANSGENE : April 27, 2021 - Transgene reports business update and end Q1 2021 ..PU
04/27 LogicBio announces clinical and corporate updates DJ
04/27 TRANSGENE : 1st quarter earningsCO
04/12 TRANSGENE : April 12, 2021 - Transgene Announces Upcoming Investor MeetingsPU
04/09 TRANSGENE : April 9, 2021 - Transgene presents initial Phase I data of TG6002, ..PU
04/07 TRANSGENE : April 7, 2021 - Availability of Preparatory Documents for the Combi..PU
04/01 TRANSGENE : April 1, 2021 - Availability of Transgene's 2020 Universal Registra..PU
04/01 TRANSGENE : ReportCO
03/30 SGS : to Support Selecta Biosciences, AskBio's Phase One Trial for Genetic Diso..MT
03/18 PRESS RELEASE : Antion Biosciences Launches Novel Cell and Gene-engineering Pla..DJ
03/17 TRANSGENE BIOTEK : in Pact to Provide Oral, Nasal Formulations for COVID-19 Vac..MT
03/10 TRANSGENE : Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Co..BU
News in other languages on TRANSGENE
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends TRANSGENE
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
HOLD
Number of Analysts
2
Average target price
3,85 €
Last Close Price
2,89 €
Spread / Highest target
55,7%
Spread / Average Target
33,2%
Spread / Lowest Target
10,7%
Please enable JavaScript in your browser's settings to use dynamic charts.
1st jan. Capitalization (M$)
TRANSGENE 75.36% 292
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
